ClinicalTrials.gg
TerminatedNCT06307626UplighTEDUpdated Mar 16, 2026

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

A Phase 3 interventional study of Efgartigimod PH20 SC and Placebo PH20 SC in Thyroid Eye Disease, sponsored by argenx. Terminated at 76 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Why this study was terminated
The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC.

After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks.

An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307613).

This study was terminated early on 15 December 2025 as the pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged. End-of-study and Safety-Follow-Up visits are ongoing for the participants of this trial.

02

Conditions studied

  • Thyroid Eye Disease

Browse trials for

03

In context

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

This study's enrollment of 105 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.

Browse Graves Ophthalmopathy studies →

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is at least 18 years of age
  • The participant is capable of providing signed and following with protocol requirements
  • The investigator determines active, moderate-to-severe thyroid eye disease (TED) associated with thyroid conditions (Graves' disease or Hashimoto's thyroiditis) for the most severely affected eye
  • The participant has first onset of active TED symptoms within 12 months before screening
  • The participant must have normal thyroid function with the baseline disease under control or have mild hypo or hyperthyroidism at screening. Every effort should be made to correct the mild hypo or hyperthyroidism promptly and to maintain the normal thyroid function for the full duration of the study
  • The participant agrees to use consistent with local regulations and the people of must have a negative blood pregnancy test at screening and a negative urine pregnancy test before receiving the study drug

Exclusion criteria

Exclusion Criteria:

  • Optic neuropathy (damage to optic nerve), defined as new visual field defect (blind spot), relative afferent pupillary defect (pupils respond differently to light), or color defect secondary to optic nerve involvement within the 6 months before screening
  • Corneal decompensation (swelling of the cornea) unresponsive to medical management
  • Previous orbital irradiation or surgery for TED
  • Use of some medications before screening (more information is found in the protocol)
  • Known disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of TED or puts the participant at undue risk
  • History of , cancer, unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer
  • active infection that is not sufficiently resolved in the investigator's opinion or positive serum test at screening for active infection with any of the following: virus (HBV), virus (HCV),
  • Current participation in another interventional clinical study or previous participation in an efgartigimod clinical study and at least 1 dose of study drug received or has received at least 1 dose of commercially available efgartigimod
  • Known to study drug or one of its (inactive ingredients)
  • History of or current alcohol, drug, or medication abuse within 12 months before screening as assessed by the investigator
  • Pregnant or lactating state or intention to become pregnant during the study
  • Live or received \<4 weeks before screening

The complete list of exclusion criteria can be found in the protocol.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Efgartigimod arm

    Participants with active, moderate-to-severe TED receiving Efgartigimod PH20 SC (subcutaneously) via pre-filled syringe (PFS)

    Combination Product: Efgartigimod PH20 SC

  • Placebo comparator
    Placebo arm

    Participants with active, moderate-to-severe TED receiving Placebo PH20 SC (subcutaneously) via pre-filled syringe (PFS)

    Other: Placebo PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants who were proptosis responders

    Time frame: At week 24 of the Double-Blinded Treatment Period

Secondary outcomes

  1. Change in proptosis measurement in the study eye from baseline

    Time frame: Up to week 24 of the Double-Blinded Treatment Period

  2. Change in the total Graves' Orbitopathy Quality of Life (GO-QoL) score from baseline

    Minimum value: 0 (most negative impact on Quality of Life); Maximum value: 100 (No impact on Quality of Life)

    Time frame: Up to week 24 of the Double-Blinded Treatment Period

  3. Percentage of participants with a resolution of diplopia (responders)

    Time frame: At week 24 of the Double-Blinded Treatment Period

07

Study locations

76 sites
  • American Institute of Research
    Los Angeles, California 90017, United States
  • North Valley Eye Medical Group, Inc.
    Mission Hills, California 91345, United States
  • Martel Eye Medical Group
    Rancho Cordova, California 95670, United States
  • Cockerham Eye Consultants
    San Diego, California 91208, United States
  • Sibia Eye Institute
    Boynton Beach, Florida 33437, United States
  • Sarasota Retina Institute (SRI)
    Sarasota, Florida 34239, United States
  • Butchertown Clinical Trials
    Louisville, Kentucky 40206, United States
  • St. Louis University (SLU) Care - Center for Specialized Medicine
    St Louis, Missouri 63104, United States
  • Advancing Research International, LLC
    Las Vegas, Nevada 89144, United States
  • New York Eye & Ear Infirmary
    New York, New York 10003, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Landeskrankenhaus - Universitaetskliniken Innsbruck
    Innsbruck, 6020, Austria
  • Hanusch-Krankenhaus - Vienna Institute for Research in Ocular Surgery
    Vienna, 1140, Austria
  • AIPSMAED Sveti Luka EOOD
    Plovdiv, 4000, Bulgaria
  • Multi-Profile Hospital for Active Treatment (MHAT) Hadji Dimitar
    Sliven, 8800, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Military Medical Academy (MMA)
    Sofia, 1606, Bulgaria
  • Peking University Third Hospital
    Beijing, 100191, China
  • The Second Affiliated Hospital of Chengdu Medical College / Nuclear Industry 416 Hospital
    Chengdu, 610066, China
  • The Second Hospital of Dalian Medical University
    Dalian, 116021, China
  • Fujian Provincial Hospital
    Fuzhou, 350001, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • Shandong Provincial Hospital of Shandong First Medical University
    Jinan, 250021, China
  • Hospices Civils de Lyon (HCL) - Hopital Louis Pradel
    Bron, 69677, France
  • CHU Lille - Hopital Huriez
    Lille, 59000, France
  • Centre Hospitalier National d'Ophtalmologie (Chno) Des Quinze-Vingts
    Paris, 75012, France
  • CHU de Saint-Etienne - Hopital Nord
    Saint-Priest-en-Jarez, 42270, France
  • JSC Curatio
    Tbilisi, 0114, Georgia
  • National Institute of Endocrinology
    Tbilisi, 0159, Georgia
  • New Hospitals
    Tbilisi, 0162, Georgia
  • Caucasus Medical Centre
    Tbilisi, 0186, Georgia
  • Universitaetsklinikum Essen (AoR)
    Essen, 45147, Germany
  • Klinikum Der Albert-Ludwigs Universitaet Freiburg
    Freiburg im Breisgau, 79106, Germany
  • Philipps-Universitaet Marburg Universitaetsklinikum Giessen und Marburg Klinik fuer Augenheilkunde
    Marburg, 35043, Germany
  • Universitaetsaugenklinik Ulm
    Ulm, 89075, Germany
  • Universita degli Studi di Cagliari - Ospedale San Giovanni di Dio
    Cagliari, 09124, Italy
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)
    Milan, 20132, Italy
  • Ospedale Cisanello
    Pisa, 56124, Italy
  • Azienda Ospedaliero Universitaria Sant'Andrea
    Roma, 00189, Italy
  • Azienda Ospedaliero Ordine Mauriziano Torino - Ospedale Umberto I di Torino
    Torino, 10128, Italy
  • Kanazawa University Hospital
    Kanazawa, 920-8641, Japan
  • Hospital of University of Occupational and Environmental Health
    Kitakyushu, 807-8555, Japan
  • Shinkoga clinic
    Kurume, 830-8522, Japan
  • Koga Hospital Group - Shinkoga Hospital
    Kurume-shi, 830-8577, Japan
  • National Hospital Organization Kyoto Medical Center
    Kyoto, 612-0861, Japan
  • Kozawa Eye Hospital and Diabetes Center
    Mito, 310-0845, Japan
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, 951-8520, Japan
  • Osaka City General Hospital
    Osaka, 534-0021, Japan
  • Hokkaido University Hospital
    Sapporo, 060-8648, Japan
  • Tohoku Medical and Pharmaceutical University - Fukumuro
    Sendai, 983-8536, Japan
  • Tottori University Hospital
    Yonago, 683-8504, Japan
  • Daugavpils Regionala Slimnica
    Daugavpils, 5417, Latvia
  • Paula Stradina Kliniska universitates slimnica
    Riga, 1002, Latvia
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • Centrum Medycyny Inwazyjnej
    Gdansk, 80-952, Poland
  • Szpital Sw. Rozy
    Krakow, 30-394, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, 93-338, Poland
  • Uniwersytecki Szpital Kliniczny w Poznaniu
    Poznan, 60-355, Poland
  • Centrum Zdrowia MDM
    Warsaw, 04-736, Poland
  • Clinical Center Vojvodina
    Novi Sad, 21000, Serbia
  • OLHB d.o.o.
    Ljubljana, 1000, Slovenia
  • University Medical Centre University Eye Hospital
    Ljubljana, 1000, Slovenia
  • Institut Catala de Retina (ICR) Centre Oftalmologic - ICR Seu Central Ganduxer
    Barcelona, 08022, Spain
  • Hospital La Arruzafa
    Córdoba, 14012, Spain
  • Hospital Universitari General de Catalunya
    Sant Cugat del Vallès, 08915, Spain
  • Hospital Clinico Universitario de Valladolid
    Valladolid, 47003, Spain
  • Eye Clinic Linkoping
    Linköping, 581 85, Sweden
  • Universitaetsspital Bern - Inselspital
    Bern, 3010, Switzerland
  • ADMEDICO Augenzentrum AG
    Olten, 4600, Switzerland
  • Memorial Ankara Hospital
    Ankara, 06520, Turkey (Türkiye)
  • Kocaeli University Research and Training Hospital
    Kocaeli, 41380, Turkey (Türkiye)
  • University Hospitals Bristol and Weston NHS Foundation Trust
    Bristol, BS13NU, United Kingdom
  • Royal Liverpool University Hospital , St Paul's Eye Unit - Liverpool University Hospitals NHS Foundation Trust
    Liverpool, L7 8XP, United Kingdom
  • Moorfields Eye Hospital
    London, EC1V 2PD, United Kingdom
  • Western Eye Hospital - Imperial College Healthcare NHS Trust
    London, NW1 5QH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Dec 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 13, 2024
StartActual
Mar 28, 2024
Primary completionActual
Dec 15, 2025
CompletionActual
Feb 12, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06307626
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Mar 28, 2024
Primary completion
Dec 15, 2025
Completion
Feb 12, 2026
Last update
Mar 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion